Sign in
Active, not recruitingPhase 2

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Key facts

Who runs it
Hellenic Institute for the Study of Sepsis
Where
Greece23 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
22 Mar 2025
Expected to end
Nov 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Emapalumab-Izsg
  • Placebo
Record updated
19 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Provide written informed consent
  • Adults (≥18 years) of male or female sex
  • Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections
  • Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more
  • Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age
  • Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay
  • Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9

Who cannot take part

  • Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
  • Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
  • Vaccination the last 12 weeks before screening with BCG vaccine
  • Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
  • Participation in any other interventional trial the last 28 days prior to day 1
  • Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
  • Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
  • Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
  • Known allergy or hypersensitivity reactions to emapalumab
  • Patients living with the human immunodeficiency virus (HIV)
  • Patients with stage IV solid or hematologic malignancy
  • Patients with neutropenia (less than 1,000 neutrophils/mm3)
  • Body weight more than 104 kg
  • Patients transplanted for solid organ or stem cells
  • Pregnancy or lactation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Standard-of-care (SoC) treatment and placebo drug.

  • Emapalumab Group 1Existing treatment, for comparison

    SoC treatment and a low dose of emapalumab.

    Treatment: Emapalumab-Izsg

  • Emapalumab Group 2Existing treatment, for comparison

    SoC treatment and a high dose of emapalumab.

    Treatment: Emapalumab-Izsg

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
19 November 2025